Emmanuel Hanon was appointed SVP of Vaccines Research and Development, GSK in October 2014. Emmanuel leads the research and development organization, covering discovery, early and late development, regulatory and medical affairs activities. He is based in Rixensart, Belgium. Emmanuel joined GSK Vaccines in 2001 taking roles of increasing responsibility in Immunology and human cell mediated immunity before leading the viral vaccines program in R&D. After heading the Elderly vaccines franchise, playing a critical role in the development of flu pre-pandemic and pandemic programs, he was appointed Senior Vice President - Vaccine Discovery and Development in August 2011. Prior to joining GSK, Emmanuel obtained a PhD at University of Liège, Belgium, in the field of Immunology and herpes virology and occupied a post-doctorate position in the field of retrovirology at Imperial College in the UK before moving to Eli Lilly as Associate Scientist in the Toxicology Department.
115C, Level 100